Please see attachment. Please read Pharmacotherapy: Principles and Practices. Chisholm-Burns et. al., eds. 5th edition. Chapters 10, 11 and 12 and include information from those chapters in this paper. The text book (Pharmacotherapy: Principles and practices (5th ed.)) recommendations are based on the 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults, National Lipid Association recommendations for patient-centered management of dyslipidemia, 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies and the 2017 focused update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol.
Guideline on the Management of Blood Cholesterol (aka 2018 Cholesterol Management Guideline) before engaging in this week’s discussion.
A 54-year-old South Asian man with diabetes mellitus, HTN, dyslipidemia, and gastroesophageal reflux disease (GERD). He is a current smoker. His current medications include lisinopril 20 mg/day, amlodipine 10 mg/day, pravastatin 40 mg/day, and omeprazole 20 mg/day. Fasting laboratory results show glucose 109 mg/dL, TC 197 mg/dL, LDL-C 128 mg/dL, HDL-C 37 mg/dL, and TG 166 mg/dL. His non-HDL is 160 mg/dL. His systolic blood pressure is 130 mmHg and the PCE (pooled Cohort Equation) estimates his 10 year risk of ASCVD to be 26.8%.
• Based on currently available guidelines and patient specific criteria given in the case, what is your plan for this patient? Be sure to include:
o Lifestyle modifications
o Drug, dose, rationale and monitoring ? …and what to do in the event there is complaints of myopathy
o Patient education Respond should be a minimum of 150 words, scholarly written, APA formatted, and referenced. A minimum of 2 references are required and no more than 7 years old.
